title: Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome.
abstract: We analysed calcitonin (CALC1) gene hypermethylation using semiquantitative differential polymerase chain reaction in 105 patients with adult (n = 49) and childhood (n = 56) acute lymphoblastic leukaemia (ALL), and studied the association of CALC1 hypermethylation with clinical presentation features and disease outcome. We also investigated the possible relationship between CALC1 methylation status and expression of the cell cycle inhibitor gene p57KIP2. We observed CALC1 hypermethylation in bone marrow cells from 43% (45 out of 105) of ALL patients. Clinical, molecular and laboratory features did not differ significantly between hypermethylated and hypomethylated patients, only T-cell lineage was associated with hypermethylation (14% vs. 47%, P = 0025). Complete remission rate was similar in both groups although hypermethylated patients had a higher relapse rate (68% vs. 19%, P < 0.00001) and mortality rate (55% vs. 36%, P = 0.06) than hypomethylated patients. Estimated disease-free survival (DFS) at 6 years was 66.1% for hypomethylated patients and 5.3% for hypermethylated patients (P < 0,00001). Multivariate analysis from potential prognostic factors demonstrated that CALC1 methylation status was an independent prognostic factor in predicting DFS (P = 0.0001). Separate analysis of adult and childhood ALL patients showed similar results to the whole series. In addition, hypermethylated patients showed downregulation of p57KIP2 expression. Our results suggest that CALC1 gene hypermethylation is associated with an enhanced risk of relapse independently of known poor-prognostic factors and we describe, for the first time, a possible implication of the p57KIP2 gene in the genesis and prognosis of ALL.
authors.affiliation: Department of Haematology, Reina Sofia Hospital, Cordoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Roman
authors.forename: J A
authors.initials: JA
authors.lastname: Castillejo
authors.forename: A
authors.initials: A
authors.lastname: Jimenez
authors.forename: R
authors.initials: R
authors.lastname: Bornstein
authors.forename: M G
authors.initials: MG
authors.lastname: Gonzalez
authors.forename: M
authors.initials: M
authors.lastname: del Carmen Rodriguez
authors.forename: M
authors.initials: M
authors.lastname: Barrios
authors.forename: J
authors.initials: J
authors.lastname: Maldonado
authors.forename: A
authors.initials: A
authors.lastname: Torres
mesh_terms: D000328:Adult; D002116:Calcitonin / Q000235:genetics*; D050761:Cyclin-Dependent Kinase Inhibitor p57; D019175:DNA Methylation; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: C493964:CDKN1C protein, human; D050761:Cyclin-Dependent Kinase Inhibitor p57; D009687:Nuclear Proteins; D002116:Calcitonin